Slide 1: Roche logo
Slide 2: Access to Healthcare ESG Investor Event
Access to Healthcare ESG Investor Event 16 May 2022
Slide 3: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 4: Welcome
Welcome Bruno Eschli | Head of Investor Relations
Slide 5: Agenda
Agenda Welcome Bruno Eschli, Head of Investor Relations Roche Sustainability Strategy Pascale Schmidt, Chief Compliance and Sustainability Officer How Roche Diagnostics enables Access to Healthcare Thomas Schinecker, CEO Roche Diagnostics Driving Access to Diagnostics across the Globe Stefan Seliger
Slide 6: Our Ambitions
Our Ambitions Keep innovating and increasing patient access to our innovations Divisional ambitions to be achieved: Pharmaceuticals: Diagnostics: • Double medical advances at less costs to • Double patient access to novel, high society by 2030 medical value diagnostics solutions • Double patient num
Slide 7: Roche Sustainability Strategy
Roche Sustainability Strategy Pascale Schmidt | Chief Compliance and Sustainability Officer
Slide 8: Our Approach to Sustainability
Our Approach to Sustainability Derived from our Purpose & Strategy Innovation Our Purpose – Highest R&D Spending in Doing now what patients need next Healthcare Industry Our Strategy CHF 13.7 billion R&D expenditure in 2021 Our Climate Goal Delivering value to all stakeholder Reducing Scope 1&2 Our
Slide 9: Sustainability Governance
Sustainability Governance Integrating sustainability into our organization 1 Corporate Governance and Sustainability Committee 1 • Responsible and accountable for governing sustainability of Board of Directors (BoD) at the BoD level • Supervises and provides advice on sustainability strategy 2 Susta
Slide 10: Our Commitment to Transparency
Our Commitment to Transparency Aligned communication on our non-financial performance Group functions External Reporting (Annual Report, Roche.com) Communications Legal and Sustainability Standards & Frameworks Procurement People & Culture Transition from 2017 GRI Standards to 2021 Business SHE Stan
Slide 11: Our External Engagement & Shaping
Our External Engagement & Shaping Global initiatives that we are actively contributing to Accelerating collectively Helping senior biotech and Accelerating the delivery the system pharma executives drive Redefining value to of net zero, sustainable Building responsible transformations needed their s
Slide 12: Our Performance in 2021
Our Performance in 2021 Supporting UN SDGs Impact 2021 performance ● ~30% decrease in our environmental impact per employee since 2019 Environment How we minimise our ● 72% of our electricity coming from sustainable sources impact on nature ● 59% decrease in greenhouse gas emissions since 2004 Econo
Slide 13: How Roche Diagnostics enables Access to Healthcare
How Roche Diagnostics enables Access to Healthcare Thomas Schinecker | CEO Roche Diagnostics
Slide 14: Trends shaping healthcare systems and access to healthcare
Trends shaping healthcare systems and access to healthcare The needs from healthcare systems, patients and for access are changing Increasing healthcare needs from Patients are empowered, taking Role of public-private partnerships aging populations action along the patient journey Healthcare systems
Slide 15: Diagnostics Strategy and our Ten-Year Ambition
Diagnostics Strategy and our Ten-Year Ambition Access to diagnostics solutions is at the core of our strategy Improve care along patient Diagnostics Ten-Year Ambition (by 2030) journeys 1 Double patient access to novel, high medical value Outcomes Enable confident healthcare diagnostics solutions Co
Slide 16: Optimizing care along the entire patient journey
Optimizing care along the entire patient journey Roche is in a unique position in the industry to address healthcare challenges Diagnostic test (i.e. IVD) Clinical Algos Remote monitoring POC Screening Patient Test program self-management Medicines GP consultation Sensors Hospitalization Medicines C
Slide 17: Disease burden and economic impact
Disease burden and economic impact Our strategy targets major disease areas to reduce impact on patients & economy Causes of death globally (millions per year)1,2 Cardiovascular diseases 18 COVID-19 >2tn CHF Infectious diseases 13 +4 20215 Cancer 10 ECONOMIC IMPACT3 Infectious diseases +100% estimat
Slide 18: Roche's impact: Disease burden
Focus on prevention and early diagnosis to bring value to patients 70% of clinical decisions informed by diagnostics but only 2% HC spend goes into it 47% 311,000 2 billion >37 million 290 million 70 million Disease burden Of population have Women every year die People with People with HIV, Chronic
Slide 19: Our contribution against COVID-19
Our contribution against COVID-19 Roche has enabled access to >1.5 billion tests to fight the COVID-19 pandemic 20+ solutions >1.5 billion COVID-19 tests Responsible pricing to >1’900 cobas® 6800/8800 enable access instruments placed1 Broad portfolio of COVID-19 Conducted with our products Costs sho
Slide 20: Impact of COVID-19 testing in Germany
Impact of COVID–19 testing in Germany Diagnostics tests reduced the negative impact on economy and healthcare system Impact of testing on society Background 2.8 million 36.5 billion 62,000 274,000 84,000 418,000 2.8 billion • COVID-19 testing1 in Germany between April 2020 euros euros and December 2
Slide 21: Global emerging and re-emerging infectious diseases
Global emerging and re-emerging infectious diseases Most of new & emerging infections occur in LMICs with limited access to diagnostics Heartland Powassan virus Lyme Disease Drug-resistant malaria Diphtheria Enterovirus D68 Typhoid fever H3N2v influenza Cryptosporidiosis E. Coli 0104:H4 Akmeta Virus
Slide 22: Driving Access to Diagnostics across the Globe
Driving Access to Diagnostics across the Globe Stefan Seliger | Head Global Access & Policy, Diagnostics Division
Slide 23: Accelerating access to diagnostics
Accelerating access to diagnostics Overcoming global and local access challenges NOT EXHAUSTIVE • Up-to-date clinical guidelines Roche access strategy implementation • Payer relevant evidence close to marketing Opportunity authorization • Across the disease areas • Local capability and healthcare ca
Slide 24: Enabling access to diagnostics solutions along the patient journey
Enabling access to diagnostics solutions along the patient journey Zooming-in on four access projects in prevention, diagnosis and management Preeclampsia Diagnosis UK HIV monitoring LMICs Elecsys® sFIt-1/PIGF ratio Plasma Separation Card Healthcare decision support Therapeutics Diagnostic solutions
Slide 25: Cervical cancer
Cervical cancer The most preventable and one of the most common cancers for women 84-90% 6x of cervical cancer incidence more likely for women with HIV to and deaths occur in LMICs1 develop cervical cancer3 19 of the top 20 600k new cases countries with the highest per year globally, expected to cer
Slide 26: The Roche cervical solution portfolio
The Roche cervical solution portfolio End-to-end solution to help countries implement national screening programs Sample collection HPV DNA screening + Diagnose cervical disease Disease management Self-sampling Screen Triage Diagnose iThemba Life increases access identify those at identify who will
Slide 27: Case study: HPV primary screening in Australia
Case study: HPV primary screening in Australia Changing national clinical practice to adopt molecular HPV screening Actions Results Supporting COMPASS trial1 (200K women) On track to become 1st country to achieve that generated local clinical and Health cervical cancer elimination Economics data2 En
Slide 28: Diversity in clinical trials
Diversity in clinical trials Evolving populations require more representative patients in clinical research Lead payor coverage Identify and activate Studies reflecting real-world disease demographics discussions to drive non-traditional trial help advance science and broaden access changes in polic
Slide 29: Preeclampsia leading cause of maternal death
Preeclampsia leading cause of maternal death Short-term prediction and appropriate management of preeclampsia Preeclampsia: 3-5% of all pregnancies disease with unpredictable onset and 4 clinical picture is not always clear1 difficult assessment of severity prognosis1 timely decision critical for mo
Slide 30: Case Study: Preeclampsia testing in UK
Case Study: Preeclampsia testing in UK Demonstrating the value of routine testing using sFLt-1 and PIGF biomarkers Actions Results Completing PROGNOSIS trial1 with local Clinical data demonstrated improved data from INSPIRE2 trial to assess impact clinical outcomes for patients on local hospitalizat
Slide 31: Pregnancy preeclampsia biomarker testing reduces costs
Pregnancy preeclampsia biomarker testing reduces costs Significant potential savings around the globe UK1 Germany2 • GBP 344 cost saving per patient • EUR 361 cost saving per patient • GBP 24 million annual saving for the NHS • EUR 39 million annual saving for the country >$1 billion est. annual glo
Slide 32: Lung cancer disease overview
Lung cancer disease overview Roche uniquely positioned to establish personalized healthcare solutions PD-L1 Positive NTRK 0.2% ROS 1 -2% RET 1 -2% HER2 1% BRAF 2% ALK 4 -5% MET 2% KRAS other 16% Pl3KCA 5% EGFR exon20 2% EGFR 10% KRAS G12C 12% FMI Database, Accessed November 2018 (all NSCLC) 32
Slide 33: Case Study: Lung Cancer testing in Chile
Case Study: Lung Cancer testing in Chile Increasing adoption of lung cancer biomarkers for targeted therapies Actions Results Partnering with Pharma division to develop Inclusion of ALK and PD-L1 IHC into access requirements national guideline Developing a series of comparative health New reimbursem
Slide 34: Diagnostics Global Access Program in 89 countries
Diagnostics Global Access Program in 89 countries Building local capacity, end-to-end solutions for sustainable elimination programs Increase access Strengthen healthcare systems Assist countries to affordable, quality diagnostics to in partnership with governments, to establish sustainable national
Slide 35: Instrument placement in LMICs
Instrument placement in LMICs Enabling LMICs to access broad portfolio of testing solutions Increasing capabilities and capacities in LMICs Investing in innovation specific for emerging market needs Medical value cobas ® 6800 Emerging market analyzer In-dev Compact and easy-to-operate Increased prof
Slide 36: Partnering across the health ecosystem
Partnering across the health ecosystem Engagement beyond labs to shape healthcare systems and better outcomes National Governments Patients Payers Patient Organizations HTA Agencies Suppliers, Private sector Regulators HCPs Parliamentarians Laboratories Professional Organizations NGOs Global Health
Slide 37: Access as a strategic imperative for Roche
Access as a strategic imperative for Roche Connecting business opportunities to patient needs and societal impact Diagnostics Ten-Year Ambition (by 2030) Double patient access to novel, high medical value diagnostics solutions Rapid Broad Sustainable Reduce time to reimbursement by 50% Geographic sc
Slide 38: In Conclusion
In Conclusion Access Continuing Integrating along the patient journey to invest in our internal access access requirements into our is central to our strategy capabilities and our local and portfolio development and global external partner network commercialization 38
Slide 39: Driving Access to Medicine across the Globe
Driving Access to Medicine across the Globe Michael Oberreiter | Head Global Access, Pharmaceuticals Division
Slide 40: Universal Health Coverage (UHC) as defined by the WHO
Universal Health Coverage (UHC) as defined by the WHO Despite progress, many countries are struggling to keep pace UHC definition by the WHO1: “...all individuals and communities receive the health services they need without suffering financial hardship. It includes the full spectrum of essential, q
Slide 41: Access challenges around the world
Access challenges around the world Barriers to treatment are significant and vary between and within countries Upper-middle and high income countries1: Low to low-middle income countries1: • Increasing healthcare costs • Lack of healthcare infrastructure and • Multiple, competing budgetary prioritie
Slide 42: Access opportunities around the world
Access opportunities around the world Significant opportunities to increase access despite challenges Upper-middle and high income countries1: Low to low-middle income countries1: • Positive economic growth • Increasing adoption of telemedicine / telehealth • Rapidly growing middle class • Cross-cou
Slide 43: Roche's six prioritised drivers of UHC (I)
Roche’s six prioritised drivers of UHC (I) Access, Innovation and Coverage of NCDs and RDs are foundational elements 1 Access Expand access to standards of care 2 Innovation Foster patient-centric innovation 3 NCDs & RDs Integrate coverage of NCDs & RDs Timely and equitable access to Environment con
Slide 44: Roche's six prioritised drivers of UHC (II)
Roche’s six prioritised drivers of UHC (II) System capacity, digital health and sustainable financing enable UHC 4 5 6 System capacity Digital & PHC Sustainable financing Contribute to enhanced Promote UHC through Enable sustainable financing health system capacity digital health and resource alloca
Slide 45: Pharma Corporate Access Goal
Pharma Corporate Access Goal Making sure that patients who need our therapies can receive them Neuroscience Oncology Immunology, Infectious diseases Rare diseases/ Orphan diseases Double patient number for our innovative medicines in LMICs by end of 2026 LMICs=Low- and middle-income countries 45
Slide 46: Pharma Corporate Access Goal
Pharma Corporate Access Goal Double patient number for our innovative medicines in LMICs by end of 2026 85 countries1, which combined represent2 +30% of the global GDP 50% of the world’s population Where over Low income 45% Lower-middle income of the world’s poor reside Established Roche presence 1W
Slide 47: Pharma Corporate Access Goal
Pharma Corporate Access Goal Opportunities to remove barriers and substantially increase access Inclusive clinical trials Regulatory filing & Affordability Capacity enablement Partnerships Access Reimbursement levers Support health equity and Substantial acceleration of Support development of Suppor
Slide 48: Pharma Corporate Access Goal
Pharma Corporate Access Goal The journey towards sustainable health financing is composed of multiple, complementary funding solutions More financial protection & sustainable, equitable access Government and compulsory insurance schemes Private funding schemes Out-of-pocket Point of care payments Ot
Slide 49: Examples of local access initiatives
Examples of local access initiatives Sustainable health financing needs multiple, complementary funding solutions Performance-based pricing Spain Canada: • Support underserved communities, including First Nations (e.g. partnership on COVID-19 research & financial support for mental health project) U
Slide 50: Access initiatives: Project ECHO using telementoring
Access initiatives: Project ECHO using telementoring Addressing lack of healthcare workers and capacity challenges Project ECHO is a video telementoring platform. It enables community caregivers to participate in guided practice to learn new medical techniques, allowing patients to receive high qual
Slide 51: Access initiatives: Cancer Health Fund in Nigeria
Access initiatives: Cancer Health Fund in Nigeria Addressing funding challenges Opportunity Action Impact Opportunity for the creation of a sustainable Roche led a private sector coalition alongside the • Funding pathway for less well off patients to funding source that: cooperation of the World Ban
Slide 52: Access initiatives: EMPOWER in Kenya
Access initiatives: EMPOWER in Kenya Addressing local infrastructure & capacity building needs through community centers Launch of EMPOWER cancer screening Community level engagements on awareness, screening and modification of health seeking behavior and treatment clinics 16 Championing for inclusi
Slide 53: Actemra & Ronapreve for SARS-CoV-2 infections
Actemra & Ronapreve for SARS-CoV-2 infections Enabling global access to innovative medicines during a global health emergency Dedicating global manufacturing network Investing into R&D 1 • Worldwide > 1mn people with severe or critical COVID-19 treated with Actemra • 250,000 doses committed at cost
Slide 54: Hemlibra in Haemophilia A
Hemlibra in Haemophilia A Enabling global access to the new standard of care Number of countries with full reimbursement1 Hemlibra, new global SOC 5 years after initial launch (inhibitor and non-inhibitor patients) • Hemophilia A, a serious bleeding disorder, is a rare genetic disease that affects 1
Slide 55: Evrysdi in Spinal Muscular Atrophy (SMA)
Evrysdi in Spinal Muscular Atrophy (SMA) Under 5 years from clinic to patient Evrysdi, most prescribed SMA treatment in the US Number of countries with reimbursement • SMA is a rare disease that affects approximately 1 in 10,000 births worldwide; Untreated, it is the most common genetic cause of inf
Slide 56: Access initiatives: Principles for evaluating impact
Access initiatives: Principles for evaluating impact Measuring success or failure and providing accountability to all stakeholders Transparent Credible Commit to third-party review, Collect high-quality data sharing, and publishing (where and use appropriate relevant) methods and results analytical
Slide 57: Tailored pricing solutions developed together with our HC partners
Tailored pricing solutions developed together with our HC partners Ensuring as many patients as possible have access to our innovations Finance-based solutions • Reviewed patient journey with local stakeholders & government to understand Manage uncertainty around the budget impact challenges; Result
Slide 58: Our pricing approach reflects WHO's fair pricing dimensions
Our pricing approach reflects WHO’s fair pricing dimensions Make innovation available for patients today and tomorrow Health impact Benefit and impact a medicine brings to patients, healthcare systems & society Future innovation System context Our pricing strategy allows us to Differentiated prices
Slide 59: Value lies in the eye of the beholder
Value lies in the eye of the beholder There is a need for mutual understanding across different stakeholders SOCIETAL POPULATION VALUE HEALTH VALUE Societal impact (e.g. Accumulated population environmental, health outcomes and employer impact) system impact Roche & industry PATIENT & WHO / NGOs / C
Slide 60: Doing now what patients need next
Doing now what patients need next